RxDoctor Payments Data

Thomas Snodell, MD

Internal Medicine · Roeland Park, KSNPI 1952307431

Payments from drug & device makers

$2,678in general payments, 2019–2025

Across 153 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$453
  • Abbott$293
  • Novo Nordisk$289
  • Pfizer$246
  • AbbVie$166
  • Amarin Pharma, Inc.$134
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,666100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,678 in reported general payments places this provider in the 85th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$207,869
Medicare patients
330
Services billed
5,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$62,923
EliquisApixaban83$62,508
XareltoRivaroxaban27$34,661
OzempicSemaglutide19$17,825
JanuviaSitagliptin Phosphate20$14,725
MyrbetriqMirabegron17$11,246
Novolog FlexpenInsulin Aspart16$4,300
Atorvastatin Calcium452$3,906
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen138$3,072
Levothyroxine Sodium338$2,997
Potassium Chloride95$2,408
Gabapentin172$2,199
Simvastatin256$1,971
Omeprazole185$1,925
Lisinopril385$1,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$35$62,92368 claims
PfizerEliquis$246$62,50883 claims
Novo NordiskOzempic$289$17,82519 claims
MerckJanuvia$16$14,72520 claims
Astellas Pharma US IncMyrbetriq$95$11,24617 claims
AbbVieSynthroid$166$1,46322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Roeland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →